Severe immune hemolytic anemia due to pemetrexed in a patient with non-small cell lung cancer

Pharmacology. 2011;88(5-6):242-4. doi: 10.1159/000331866. Epub 2011 Oct 12.

Abstract

Pemetrexed-induced immune hemolytic anemia is a rare acute complication and a potentially life-threatening syndrome. Here we report a case of severe hemolytic anemia induced by pemetrexed in a 67-year-old man with lung adenocarcinoma. Hemoglobin concentration reached a nadir of 6.8 g/dl after 6 days of pemetrexed initiation. Pemetrexed was discontinued and the patient was given a transfusion of red blood cells. The direct antiglobulin test was positive (anti-IgG = 4+, anti-C3d = 2+). The patient's plasma reacted with pemetrexed-treated red blood cells by the immune complex test.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / blood*
  • Adenocarcinoma / drug therapy
  • Aged
  • Anemia, Hemolytic / blood
  • Anemia, Hemolytic / chemically induced*
  • Antimetabolites, Antineoplastic / adverse effects*
  • Carcinoma, Non-Small-Cell Lung / blood*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Erythrocyte Indices
  • Glutamates / adverse effects*
  • Guanine / adverse effects
  • Guanine / analogs & derivatives*
  • Humans
  • Male
  • Pemetrexed
  • Thymidylate Synthase / antagonists & inhibitors

Substances

  • Antimetabolites, Antineoplastic
  • Glutamates
  • Pemetrexed
  • Guanine
  • Thymidylate Synthase